SLSSELLAS Life Sciences Group, Inc.

Sign up free
⚡

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 - Yahoo Finance

Yahoo Finance · Nov 4, 2:00 PM

Market reactionShares fell 14% on Nov 5.

IntactLast material event Aug 11, 2026 · Updated Oct 29, 2026

GPS enters REGAL final analysis; SLS009 first-line AML data remain expected Q4 2026

SELLAS Life Sciences is a clinical-stage company with two leukemia drugs: GPS, a vaccine in a Phase 3 trial, and SLS009, a targeted drug in Phase 2; neither is approved.

SELLAS's lead program, GPS, depends on the Phase 3 REGAL overall-survival result in AML patients in second complete remission. The 80th event has occurred, triggering final analysis, with preliminary topline results promised this quarter. SLS009 remains the second program, with an 80-patient Phase 2 first-line AML trial and topline data expected in Q4 2026. A REGAL disappointment would shift the investment case toward SLS009. Cash supports planned development, but additional funding will be needed through profitability.

Thesis checklist

0 risks need attention

Select a row for evidence
REGAL shows GPS extends survivalAwaiting evidenceNext: Preliminary topline overall-survival results, which SELLAS says it will announce this quarter.

Why it is in this state

The evidence, what would weaken it and the source filing

SLS009 works in first-line AMLAwaiting evidenceNext: First-line AML topline data, expected in Q4 2026.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash funds both readoutsSupportedNext: Next cash update and spending plans for potential GPS approval preparations and continued SLS009 development.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

REGAL final overall-survival results

Tests: REGAL shows GPS extends survival

Q4 2026, after database lock and analysis

Does GPS improve overall survival versus best available treatment in AML patients in second complete remission?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
+6.5%Aug 11, 2026

GPS enters REGAL final analysis; SLS009 first-line AML data remain expected Q4 2026

IntactClinical
+25.1%May 12, 2026

SELLAS pivots on two AML bets: GPS Phase 3 REGAL final analysis and SLS009 first-line trial define whether either program reaches approval

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Acute myeloid leukemia· complete remission post-second-line salvage
GPS · 1 upcoming
Phase 3 Data: FinalREGAL
Q4 2026
Acute myeloid leukemia· newly diagnosed first-line
SLS009 · 1 upcoming
Phase 2 Data: Topline
Q4 2026
Pancreatic ductal adenocarcinoma· RAS inhibitor-resistant
SLS009 · 1 upcoming
Study Initiation
TBD
Acute myeloid leukemia· newly diagnosed and early-refractory to azacitidine-venetoclax
SLS009 · 1 completed
Study Initiation
Reported Mar 19, 2026
Acute myeloid leukemia· relapsed/refractory
SLS009 · 1 completed
Phase 2 Data: Final
Reported Aug 12, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the SELLAS Life Sciences Group (SLS) investment thesis intact?
Yes. Readouts currently rates the SELLAS Life Sciences Group Thesis Intact. GPS enters REGAL final analysis; SLS009 first-line AML data remain expected Q4 2026.
What is the next catalyst for SELLAS Life Sciences Group (SLS)?
The next dated event is Phase 2 topline results for SLS009, expected Q4 2026, as stated by the company. Also ahead: Phase 3 final results (REGAL) for GPS, expected Q4 2026.
How long will SELLAS Life Sciences Group's cash last?
SELLAS Life Sciences Group has said its cash will fund operations beyond Aug 2027 (guidance as of August 11, 2026).

Other companies we cover in these diseases

Disease areas: Blood cancers, Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.